Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LCFA-01 and LC103 in Bacterial Vaginosis
NCT07875673Phase 1Not yet recruiting
- Sponsor
- Massachusetts General Hospital
- Start
- Feb 2027
- Primary completion
- Feb 2028
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of oleic acid in bacterial vaginosis (BV) (5 arms), sponsored by Massachusetts General Hospital. Primary endpoints: Treatment-Emergent Adverse Events, Serious Adverse Events and 8 more. Planned start Feb 2027; status: not yet recruiting.
02
Drugs
oleic acid
03
Conditions
bacterial vaginosis (BV)
Beyond the preview
Go deeper on NCT07875673.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07875673.